- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871934
Integrating Pharmacogenetics In Clinical Care (I-PICC)
Clinical Safety and Efficacy of Pharmacogenetics in Veteran Care
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Variants at rs4149056 in the SLCO1B1 gene are associated with a greater risk of simvastatin-related myopathy. Despite the growing implementation of SLCO1B1 rs4149056 genotyping in health systems across the United States, there is little randomized controlled trial data on the impact of SLCO1B1 testing on clinical outcomes. The IPICC Study will use a randomized design to determine the impact of the clinical integration of SLCO1B1 genotype testing on important patient outcomes, including statin prescribing, LDL cholesterol, and statin-related myopathy. In addition, by enrolling statin-naive patients with a recent cholesterol panel, this trial will capture a moment of clinical decision-making when SLCO1B1 rs4149056 genotype might be most clinically relevant. This randomized-control trial has two primary aims:
Aim 1 (Drug safety): To determine the impact of SLCO1B1 pharmacogenetic testing on concordance with Clinical Pharmacogenetics Implementation Consortium (CPIC) pharmacogenetic guidelines for safe simvastatin prescribing and on the incidence of statin-related myopathy in VA (drug safety).
Aim 2 (Cardiovascular disease, CVD, prevention): To determine the impact of SLCO1B1 pharmacogenetic testing on LDL cholesterol levels and concordance with CVD prevention guidelines.
The I-PICC Study is enrolling 408 statin-naive primary care and women's health patients across the Veteran Affairs Boston Healthcare System. Eligible patients are aged 40-75 and have elevated risk of cardiovascular disease (CVD) according to American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Primary care providers (PCPs) are also research subjects and consent via electronic health record (EHR) alerts. To model pharmacogenotyping at the point of care, the investigators are enrolling patients with recent cholesterol results when their PCPs order laboratory testing, indicating a moment of clinical decision-making about CVD risk. Enrolled patients are randomized to have their PCPs receive results through the EHR immediately (PGx+) vs. after 1 year (PGx-). The investigators will query clinical and pharmacy data for 1-year outcomes: myopathy and concordance with CPIC simvastatin guidelines (drug safety) and cholesterol levels and concordance with ACC/AHA guidelines (CVD risk reduction).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02130
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Providers:
- All providers in Primary Care and Women's Health at VA Boston Healthcare System will be eligible to participate.
Patients:
- Aged 40-75 years
- Have no history of statin use
- Have received VA care for at least the prior 6 months
- Are a patient of an enrolled provider
Meet at least 1 of the following criteria:
- cardiovascular disease (CVD)
- diabetes
- LDL cholesterol value >= 190 mg/dL
- 10-year CVD risk of 7.5%, calculated with the ACC/AHA 2013 pooled risk equations
Exclusion Criteria:
Patients will be ineligible if they:
- Do not meet the inclusion criteria
- Pregnant
- Incarcerated or institutionalized
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PGx+
Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
|
Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
Other Names:
|
Experimental: PGx-
Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
|
Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-Month Change in LDL Cholesterol
Time Frame: 12 months
|
The primary CVD prevention outcome is 12-month change in low-density lipoprotein (LDL) cholesterol, defined as LDL value at 12 months minus LDL value at baseline.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With an American College of Cardiology/American Heart Association (ACC/AHA) Guideline Concordant Statin Prescription at 12 Months
Time Frame: 12 months
|
In 2013, the ACC/AHA endorsed guidelines that recommended prescribing statins of specific intensities (moderate or high) for distinct populations.
Using patient characteristics and prescription data, the investigators will generate a 2-level CVD prevention outcome (concordant vs. non-concordant) for each participant, a measure of whether a patient's statin prescription is adequate for his/her level of CVD risk.
|
12 months
|
Number of Participants With Chart Review Documented Statin-related Myotoxicity at 12 Months
Time Frame: 12 months
|
Chart review of all patient notes during the 12 months after enrollment will be used to determine the proportion of patients in each arm who experienced statin-related muscle side effects during the observation period.
|
12 months
|
Number of Participants Meeting Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Safe Simvastatin Prescription at 12 Months
Time Frame: 12 months
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend specific simvastatin doses when a patient's SLCO1B1 genotype is known.
The investigators will compare each patient's medication prescriptions one year after enrollment to this guideline to generate a 2-level safety outcome (potentially safe vs. potentially unsafe simvastatin prescription) for each participant.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant Response Distributions to Belief in Medications Questionnaire at 12 Months
Time Frame: 12 months
|
Assessed by phone survey 12 months after enrollment.
Consists of 2 items: "Do you agree or disagree with these statements?: "My health in the future will depend on my medicines" and "Medicines do more harm than good."
|
12 months
|
Number of Participants Recalling Pharmacogenetic Testing at 12 Months
Time Frame: 12 months
|
Assessed by phone survey 12 months after enrollment.
Whether patient remembers receiving PGx results from provider and, if so, remembers the results and interpretation.
|
12 months
|
Number of Participants Reporting Statin-related Muscle Side Effects at 12 Months
Time Frame: 12 months
|
Assessed by phone survey 12 months after enrollment.
Whether patient attributes muscle pains, weakness, or cramps to a statin taken in the prior 12 months.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jason L Vassy, MD MPH, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Publications and helpful links
General Publications
- Vassy JL, Brunette CA, Majahalme N, Advani S, MacMullen L, Hau C, Zimolzak AJ, Miller SJ. The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care. Contemp Clin Trials. 2018 Dec;75:40-50. doi: 10.1016/j.cct.2018.10.010. Epub 2018 Oct 24.
- Vassy JL, Gaziano JM, Green RC, Ferguson RE, Advani S, Miller SJ, Chun S, Hage AK, Seo SJ, Majahalme N, MacMullen L, Zimolzak AJ, Brunette CA. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial. JAMA Netw Open. 2020 Dec 1;3(12):e2027092. doi: 10.1001/jamanetworkopen.2020.27092.
- Brunette CA, Miller SJ, Majahalme N, Hau C, MacMullen L, Advani S, Ludin SA, Zimolzak AJ, Vassy JL. Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study. Clin Transl Sci. 2020 Mar;13(2):381-390. doi: 10.1111/cts.12723. Epub 2019 Dec 18.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPLC-006-15S
- IK2CX001262 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on SLCO1B1 Genotype
-
Duke UniversityDavid Grant U.S. Air Force Medical CenterCompletedHypercholesterolemia | Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse ReactionUnited States
-
Mayo ClinicRecruitingBreast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Lobular Carcinoma In SituUnited States
-
Duke UniversityCompletedHypercholesterolemia | HMG COA Reductase Inhibitor Adverse ReactionUnited States
-
Masonic Cancer Center, University of MinnesotaNational Cancer Institute (NCI)Completed
-
University of VirginiaAmerican Heart AssociationRecruitingIschemic Stroke | CYP2C19 PolymorphismUnited States
-
Capital Medical UniversityUnknown
-
Utrecht Institute for Pharmaceutical SciencesUppsala University; Erasmus Medical Center; Newcastle University; University of... and other collaboratorsCompletedVenous Thromboembolism (VTE) | Atrial Fibrillation (AF)Germany, Austria, Netherlands
-
Utrecht Institute for Pharmaceutical SciencesUppsala University; Erasmus Medical Center; Newcastle University; University of... and other collaboratorsCompletedAtrial Fibrillation | Venous ThromboembolismNetherlands, Greece
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States
-
University of FloridaTerminatedChemotherapy | Supportive Care | GenotypingUnited States